DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Litton JK, Blum JL, Eiermann W et al.
A phase 3, open-label, randomized, parallel, 2-arm multi-center study of the oral PARP inhibitor BMN 673 versus physicianʼs choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA study).
San Antonio Breast Cancer Symposium; 2014 OT1-1–12
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.